Clinical trials: Kidney Disorder
Chronic Kidney Disease
Low Phosphate Diets in Patients With Early Stages of Chronic Kidney Disease
The purpose of this study is to learn more about how the kidneys control the blood levels of phosphorus in patients with early chronic kidney disease.
- Trial name
- NCT00438932
- Testing
- Lanthanum Carbonate, Low Phosphorus Diet, Unrestricted Phosphorus Diet
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Massachusetts General Hospital
Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH treatment trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back…
- Conditions
- Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Trial name
- NCT03213652
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan
- Where
- 126 sites in United States, Australia and 2 more
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
End-stage Renal Disease
Improved Induction and Maintenance Immunosuppression in Kidney Transplantation
This 2 x 2 sequential factorial study evaluates two potential improvements to the standard immunosuppression regimen used at the investigators' institution to prevent rejection of transplanted kidneys.
- Trial name
- NCT00556933
- Testing
- rabbit anti-thymocyte globulin - single dose, mycophenolate mofetil, rabbit anti-thymocyte globulin - 4 doses
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- University of Nebraska
Treatment Resistant Nephrotic Syndrome
Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)
This study will examine the safety and effectiveness of ACTHAR Gel, when used to treat 15 patients diagnosed with "treatment resistant nephrotic syndrome." Nephrotic syndrome is a group of symptoms that includes low levels of…
- Trial name
- NCT01129284
- Testing
- ACTHAR gel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Columbia University
Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency
Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency
An Open-Label, Repeated-Dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Oral CTAP101 Capsules, Immediate- Release (IR) Calcifediol, High-Dose Cholecalciferol, and Paricalcitol Plus Low-Dose Cholecalciferol in…
- Conditions
- Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency, CKD Stage 3, CKD Stage 4
- Trial name
- NCT03588884
- Testing
- Calcifediol Oral Capsule, Calcifediol Oral Product, Cholecalciferol
- Where
- 3 sites in United States
- Volunteers
- 69 people
- Sponsor
- OPKO Health, Inc.
Chronic Kidney Disease, Cardiovascular Disease
Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra)
There has been an exponential growth in the number of people with Chronic Kidney Disease (CKD) needing dialysis or transplantation, increasing from 209,000 in 1991 to 472,000 in 2004.
- Trial name
- NCT00897715
- Testing
- Rilonacept
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- VA Office of Research and Development
Esophageal Neoplasms, Lung Neoplasms
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
Background: Mithramycin is a new cancer drug. In another study, people with chest cancer took the drug 6 hours a day for 7 straight days. Many of them had liver damage as a side effect.
- Conditions
- Esophageal Neoplasms, Lung Neoplasms, Mesothelioma, Thymus Neoplasms
- Trial name
- NCT02859415
- Testing
- Mithramycin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Kidney Disease
A Study to Assess the Relative Bioavailability of 3 Different Formulations Under Fasted and Fed Condition
This study is intended to assess the relative bioavailability between the (extended-release) ER8 capsule formulation (the formulation that is currently used for verinurad development) given under fasted conditions and 2 new…
- Trial name
- NCT04024501
- Testing
- Verinurad ER8 capsule formulation (fasted), Verinurad A-capsule formulation (fasted), Verinurad A-capsule formulation (fed)
- Where
- Germany
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Kidney Disease
A Study in Healthy Subjects to Assess Drug Availability of 4 Different Formulations of Verinurad and Allopurinol
This study is a single centre, randomised, open-label, single-dose, 5-period, 5-treatment, crossover study in healthy male and female subjects.
- Trial name
- NCT04550234
- Testing
- Verinurad prolonged release HPMC capsule, Allopurinol Tablet, Verinurad/Allopurinol FDC Capsule
- Where
- Germany
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Renal Insufficiency, Type 2 Diabetes Mellitus
A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009)
This is a 2-part study in participants with renal impairment and matched healthy participants to investigate the effect of impaired renal function on the plasma and urine levels of omarigliptin (MK-3102) after taking a single 3…
- Trial name
- NCT01407276
- Testing
- Omarigliptin
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
End-stage Renal Disease
Vitamin D and Arteriovenous Fistulae
Patients requiring hemodialysis following kidney failure need a form of dialysis vascular access in order to undergo the dialysis procedure. Dialysis vascular access dysfunction is an enormous clinical problem.
- Trial name
- NCT00912782
- Testing
- Vitamin D3
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Emory University
Renal Cell Carcinoma
Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma
This is a Phase II, open-label, safety, pharmacodynamic and efficacy study of entinostat in combination with nivolumab and ipilimumab in subjects with metastatic renal cell carcinoma (RCC) who have progressed on ipilimumab +…
- Trial name
- NCT03552380
- Testing
- Entinostat, Nivolumab, Ipilimumab
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Roberto Pili
Renal Failure
Comparing Everolimus and Sirolimus in Renal Transplant Recipients
This study is being done to compare the effectiveness and safety of two different kidney transplant immunosuppression drugs, Zortress (the study drug) and Rapamune (which is used in the current standard immunosuppression regimen).
- Trial name
- NCT01976390
- Testing
- Everolimus, Sirolimus
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Ohio State University
Coronary Artery Disease, Diabetes Mellitus
Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease
Patients with diabetes mellitus (DM) are at increased risk of atherothrombotic events. Importantly, DM is a key risk factor for the development of chronic kidney disease (CKD), which further enhances atherothrombotic risk.
- Trial name
- NCT02539160
- Testing
- ticagrelor
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- University of Florida
Contrast Media Reaction, Acute Renal Failure
IVUS Guidance to Reduce Contrast in Coronary Angioplasty
This study tests the hypothesis that ultrasound-guided PCI reduces contrast volume during the procedure.
- Trial name
- MOZART (NCT01947335)
- Testing
- IVUS-guided PCI
- Where
- Brazil
- Volunteers
- 83 people
- Sponsor
- InCor Heart Institute
ESRD
Interventions Made to Preserve Cognitive Function
This is a randomized, controlled trial to slow cognitive decline in adults undergoing hemodialysis (HD). The investigators will test three interventions cognitive training (CT), exercise training (ET), and combined cognitive and…
- Trial name
- IMPCT (NCT03616535)
- Testing
- Cognitive training, Exercise training, Combined cognitive and exercise training
- Where
- 2 sites in United States
- Volunteers
- 130 people
- Sponsor
- Johns Hopkins University
Renal Stone
High Versus Low Power Settings During Ureteroscopic Laser Lithotripsy
The primary aim of the study is to compare the operative times following ureteroscopic lithotripsy for renal stones with Thulium Fiber Laser using low and high power settings.
- Trial name
- NCT05697250
- Testing
- Laser power settings (Thulium Fiber Laser)
- Where
- Norway
- Volunteers
- 150 people
- Sponsor
- Haukeland University Hospital
Anhydramnios, Potter Syndrome
Renal Anhydramnios Fetal Therapy
Early pregnancy renal anhydramnios (EPRA) is a condition where a pregnant woman does not have any amniotic fluid around her fetus because of a problem with the fetus's kidneys.
- Conditions
- Anhydramnios, Potter Syndrome, Lung Hypoplasia, Multicystic Dysplastic Kidney
- Trial name
- RAFT (NCT03101891)
- Testing
- Serial amnioinfusions with isotonic fluid, Spinal needle, Isotonic fluid
- Where
- 9 sites in United States
- Volunteers
- 55 people
- Sponsor
- Johns Hopkins University
Coronary Artery Stenosis
Kidney Damage in Patients With Moderate Fall in eGFR
To compare Iopamidol injection 370 and Iodixanol 320 in evaluating Neutrophil Gelatinase-Associated Lipocalin (NGAL) in patients with moderate fall in eGFR
- Trial name
- NCT01136876
- Testing
- Iopamidol, Iodixanol-320
- Where
- 4 sites in United States, Canada
- Volunteers
- 57 people
- Sponsor
- Bracco Diagnostics, Inc
Acute Kidney Injury, Nephrotoxicity
Assessment of Urinary NGAL to Predict AKI in Children Receiving Multiple Nephrotoxic Medications
Nephrotoxic medication (NTMx) exposure is one of the most commonly cited causes of acute kidney injury (AKI) in hospitalized children, and is the primary cause of AKI in 16% of cases.
- Trial name
- NINJA NGAL (NCT03527160)
- Where
- 2 sites in United States
- Volunteers
- 134 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.